Literature DB >> 9541100

Counselling issues in familial hypertrophic cardiomyopathy.

B Yu1, J A French, R W Jeremy, P French, D R McTaggart, M R Nicholson, C Semsarian, D R Richmond, R J Trent.   

Abstract

To illustrate the variable clinical presentations and rates of progression in familial hypertrophic cardiomyopathy (FHC), phenotypes and genotypes were compared in three FHC families with different genetic defects. In the first family, the FHC abnormality was a protein truncating mutation (Gln969X) in the cardiac myosin binding protein C gene. The second family had a missense change (Asn755Lys) in the same gene. A missense mutation (Arg453Cys) in the cardiac beta myosin heavy chain gene was present in the third family. Penetrance associated with the Gln969X defect was 27% in the age range 0 to 40 years. This was considerably less than the 93% penetrance (0 to 40 years) observed in the two families with missense mutations. The variable penetrance in FHC, as well as the unpredictability of sudden cardiac death, complicates clinical diagnosis and management, including genetic counselling. Although a genetic disease with a predominantly adult onset, there are counselling issues in FHC which set it aside from other adult onset disorders.

Entities:  

Mesh:

Year:  1998        PMID: 9541100      PMCID: PMC1051239          DOI: 10.1136/jmg.35.3.183

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  Genetic testing for familial hypertrophic cardiomyopathy in newborn infants.

Authors:  M P Ryan; J French; S al-Mahdawi; P Nihoyannopoulos; J G Cleland; C M Oakley; P S Harper; A Clarke; J Davis; L Grigg
Journal:  BMJ       Date:  1995-04-01

2.  DNA testing in familial hypertrophic cardiomyopathy: clinical and laboratory implications.

Authors:  R V Smart; B Yu; H Le; J A French; D R Richmond; R W Jeremy; C Semsarian; L Cheung; D A Ross; R J Trent
Journal:  Clin Genet       Date:  1996-10       Impact factor: 4.438

Review 3.  Molecular basis of familial cardiomyopathies.

Authors:  K Schwartz; L Carrier; P Guicheney; M Komajda
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

Review 4.  Hypertrophic cardiomyopathy--pathology and pathogenesis.

Authors:  M J Davies; W J McKenna
Journal:  Histopathology       Date:  1995-06       Impact factor: 5.087

5.  Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families.

Authors:  W J McKenna; P Spirito; M Desnos; O Dubourg; M Komajda
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

6.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle.

Authors:  K Poetter; H Jiang; S Hassanzadeh; S R Master; A Chang; M C Dalakas; I Rayment; J R Sellers; L Fananapazir; N D Epstein
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

7.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles.

Authors:  B J Maron; J Shirani; L C Poliac; R Mathenge; W C Roberts; F O Mueller
Journal:  JAMA       Date:  1996-07-17       Impact factor: 56.272

8.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy.

Authors:  R Anan; G Greve; L Thierfelder; H Watkins; W J McKenna; S Solomon; C Vecchio; H Shono; S Nakao; H Tanaka
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 9.  The management of hypertrophic cardiomyopathy.

Authors:  P Spirito; C E Seidman; W J McKenna; B J Maron
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245

10.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy.

Authors:  H Watkins; W J McKenna; L Thierfelder; H J Suk; R Anan; A O'Donoghue; P Spirito; A Matsumori; C S Moravec; J G Seidman
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

View more
  4 in total

1.  Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease.

Authors:  B Yu; N A Sawyer; M Caramins; Z G Yuan; R B Saunderson; R Pamphlett; D R Richmond; R W Jeremy; R J Trent
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

2.  Impediments to DNA testing and cascade screening for hypertrophic cardiomyopathy and Long QT syndrome: a qualitative study of patient experiences.

Authors:  Andrew Smart
Journal:  J Genet Couns       Date:  2010-08-03       Impact factor: 2.537

3.  Genetic Counseling and Screening Issues in Familial Dilated Cardiomyopathy.

Authors:  E L Hanson; R E Hershberger
Journal:  J Genet Couns       Date:  2001-10       Impact factor: 2.537

Review 4.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Ray E Hershberger; Jason Cowan; Ana Morales; Jill D Siegfried
Journal:  Circ Heart Fail       Date:  2009-05       Impact factor: 8.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.